News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Demonstrate significant bleed reduction in hemophilia A and B
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated
